Search hospitals > Pennsylvania > Bryn Mawr
Bryn Mawr Hospital
Claim this profileBryn Mawr, Pennsylvania 19010
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Adenocarcinoma
249 reported clinical trials
6 medical researchers
Summary
Bryn Mawr Hospital is a medical facility located in Bryn Mawr, Pennsylvania. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Bryn Mawr Hospital is involved with conducting 249 clinical trials across 255 conditions. There are 6 research doctors associated with this hospital, such as Albert DeNittis, MD, Paul B. Gilman, Deric C. Savior, and John G. Devlin.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
HER2 positive
2Breast Cancer
Global LeaderER positive
HER2 positive
HER2 negative
Top PIs
Albert DeNittis, MDLankenau Medical Center4 years of reported clinical research
Expert in Cancer
Expert in Lung Cancer
59 reported clinical trials
120 drugs studied
Paul B. GilmanRiddle Memorial Hospital3 years of reported clinical research
Studies Cancer
Studies Non-Small Cell Lung Cancer
14 reported clinical trials
43 drugs studied
Deric C. SaviorPaoli Memorial Hospital2 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
11 reported clinical trials
27 drugs studied
John G. DevlinRiddle Memorial Hospital9 years of reported clinical research
Studies Cancer
Studies Non-Small Cell Lung Cancer
4 reported clinical trials
10 drugs studied
Clinical Trials running at Bryn Mawr Hospital
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Ovarian Cancer
Pancreatic Cancer
Fallopian Tube Cancer
Squamous Cell Carcinoma
Gastric Cancer
Esophageal Adenocarcinoma
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Bryn Mawr Hospital?
Bryn Mawr Hospital is a medical facility located in Bryn Mawr, Pennsylvania. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Bryn Mawr Hospital is involved with conducting 249 clinical trials across 255 conditions. There are 6 research doctors associated with this hospital, such as Albert DeNittis, MD, Paul B. Gilman, Deric C. Savior, and John G. Devlin.